QPS, a CRO supporting discovery, preclinical and clinical drug development, is expanding its U.S.-based Translational Medicine division, which supports nucleic acid therapeutics. The expansion at its Newark, DE site allows QPS to support additional partners for next-generation drug therapies. “Gene therapy will become important in treating, and possibly curing, the neediest of more than 1.5 billon people who have mutations linked to genetic diseases,” said John L. Kolman, Ph.D., v...